Seth P. Lerner, MD, presented “Neoadjuvant/Adjuvant Chemotherapy: Are We Ready to Accept NAC as the Gold Standard?” during the 3rd Annual International Bladder Cancer Update on January 23, 2019 in Beaver Creek, Colorado.
How to cite: Lerner, Seth P. “Neoadjuvant/Adjuvant Chemotherapy: Are We Ready to Accept NAC as the Gold Standard?” January 23, 2019. Accessed May 2021. https://dev.grandroundsinurology.com/neoadjuvant-adjuvant-chemotherapy-are-we-ready-to-accept-nac-as-the-gold-standard/
Neoadjuvant/Adjuvant Chemotherapy: Are We Ready to Accept NAC as the Gold Standard? – Summary:
Seth P. Lerner, MD, provides the rationale for integrating perioperative chemotherapy and radical cystectomy, describes the evidence supporting neoadjuvant chemotherapy (NAC), and reviews the limited evidence supporting adjuvant therapy for patients with bladder cancer. He then discusses the future of predictive biomarkers and precision medicine in the management of this disease.
About the International Bladder Cancer Update
The International Bladder Cancer Update (IBCU) is an annual one-day CME conference focused on bladder cancer treatment updates. IBCU takes place during its sister conference, the International Prostate Cancer Update (IPCU). The conference’s faculty consists of international experts, and the event caters to urologists, urologic oncologists, and other healthcare professionals. In addition to didactic lectures, IBCU features interactive discussions, a panel roundtable, debates, and case presentations. Dr. Lerner presented this lecture during the 3rd IBCU in 2019. Please visit this page in order to learn more about future IBCU meetings.